Suboxone (Buprenorphine / Naloxone) Taper: A Comparison of Taper Schedules Walter Ling, Ph.D. Lead Investigator Director, Integrated Substance Abuse Programs, UCLA 11075 Santa Monica Boulevard Suite 225 Los Angeles, CA 90025 lwalter@ix.netcom.com

For decades clinicians have been frustrated by the inability to successfully detoxify opiate addicted patients because opiate-based detoxification, one of the most effective means to achieving that goal, has been unavailable outside the very restrictive confines of narcotic treatment programs (NTPs). A new medication, Buprenorphine, shows promise as an effective aid for opiate detoxification. However, little data have been generated for the shorter-term use of Buprenorphine/Naloxone (Suboxone) for this indication. This protocol will compare the clinical utility of two dosage tapering regimens (7 days and 28 days) in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.

LATEST PUBLICATIONS AND DATA

	Find publications in the Library about Protocol CTN-0003
	Researchers: Data from this protocol is available from CTN Public Datashare.